Enhertu Plus Pertuzumab Approved in the U.S. as First New Treatment in a Decade for the 1st-Line Treatment of Patients With HER2-Positive Metastatic Breast Cancer
December 16, 2025
December 16, 2025
WILMINGTON, Delaware, Dec. 16 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca
and Daiichi Sankyo's ENHERTU in combination with pertuz . . .
* * *
ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca
and Daiichi Sankyo's ENHERTU in combination with pertuz . . .